The KRT8 Knockout 786-O Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 786-O renal cell adenocarcinoma line. This population carries a targeted disruption of the KRT8 gene, resulting in loss of keratin 8 protein expression. The polyclonal format encompasses a spectrum of knockout alleles, enabling analysis of heterogeneous cellular responses. This model is suitable for a wide range of functional and mechanistic studies in epithelial cell biology and cancer research.
The host cell line 786-O originates from a human clear cell renal cell carcinoma (ccRCC) and harbors a VHL tumor suppressor gene mutation. VHL inactivation leads to constitutive stabilization of hypoxia-inducible factors (HIFs), driving a pseudohypoxic transcriptional program that promotes angiogenesis, metabolic shift, and tumor progression. This establishes 786-O as a standard model for ccRCC, facilitating investigation of oncogenic mechanisms and therapeutic vulnerabilities. The integration of KRT8 knockout within this VHL-mutant context allows researchers to explore how keratin 8 deficiency interacts with dysregulated HIF signaling.
KRT8 encodes keratin 8, a type II intermediate filament protein that pairs obligatorily with keratin 18 (KRT18) to form cytoplasmic filaments essential for maintaining epithelial mechanical integrity. These filaments connect to desmosomal cell-cell junctions through interactions with desmoplakin and plakoglobin, thereby linking the cytoskeleton to cell adhesion complexes. KRT8 expression is modulated by upstream signals including epidermal growth factor (EGF), transforming growth factor-beta (TGF-??), and the tumor suppressor p53. Downstream, KRT8 influences the organization and stability of KRT18, desmoplakin, and adhesion complexes, impacting cell migration, polarization, and survival.
In the 786-O ccRCC background, disruption of KRT8 provides a model to assess the contribution of keratin intermediate filaments to tumor cell mechanics and malignancy. VHL-mutant cells often exhibit altered adhesion and invasive properties, processes in which keratin networks are deeply involved. The KRT8 knockout polyclonal population allows investigation of how loss of this structural protein affects cytoskeletal organization, cell motility, and response to microenvironmental cues. Such studies may reveal dependencies or compensatory mechanisms that can be targeted in renal cell carcinoma.
These polyclonal knockout cells are suited for a variety of experimental approaches including Western blotting to confirm loss of KRT8 protein, immunofluorescence to visualize intermediate filament network disruption, and wound healing or transwell migration assays to quantify motility changes. Viability assays under stress conditions can be employed to evaluate the role of KRT8 in cell survival, while co-culture or 3D spheroid models may uncover effects on tissue-like organization. The cells can also be utilized in drug screening to identify compounds that selectively affect keratin-deficient tumor cells. For further details, please contact Ascent Research.
